Molecular targeting of renal cell carcinoma by an oral combination

The 5-year survival rate of patients with metastatic renal cell carcinoma (mRCC) is <12% due to treatment failure. Therapeutic strategies that overcome resistance to modestly effective drugs for mRCC, such as sorafenib (SF), could improve outcome in mRCC patients. SF is terminally biotransformed...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncogenesis
Huvudupphovsmän: Jordan, Andre R., Wang, Jiaojiao, Yates, Travis J., Hasanali, Sarrah L., Lokeshwar, Soum D., Morera, Daley S., Shamaladevi, Nagarajarao, Li, Charles S., Klaassen, Zachary, Terris, Martha K., Thangaraju, Muthusamy, Singh, Amar B., Soloway, Mark S., Lokeshwar, Vinata B.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7237463/
https://ncbi.nlm.nih.gov/pubmed/32427869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-020-0233-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk